Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib.

Casavecchia G, Galderisi M, Novo G, Gravina M, Santoro C, Agricola E, Capalbo S, Zicchino S, Cameli M, De Gennaro L, Righini FM, Monte I, Tocchetti CG, Brunetti ND, Cadeddu C, Mercuro G.

Heart Fail Rev. 2020 Feb 5. doi: 10.1007/s10741-020-09926-y. [Epub ahead of print] Review.

PMID:
32026180
2.

Ponatinib in the therapy of chronic myeloid leukemia.

Poch Martell M, Sibai H, Deotare U, Lipton JH.

Expert Rev Hematol. 2016 Oct;9(10):923-32. doi: 10.1080/17474086.2016.1232163. Review.

PMID:
27590270
3.

A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, O'Hare T, Yan Y.

Leukemia. 2016 Jul;30(7):1493-501. doi: 10.1038/leu.2016.51. Epub 2016 Mar 8.

4.

Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.

Bardy-Bouxin N, Matczak E, Devgan G, Woloj M, Shapiro M.

Biologics. 2015 Feb 19;9:23-4. doi: 10.2147/BTT.S79507. eCollection 2015. No abstract available.

5.

Bosutinib for the Treatment of Philadelphia Chromosome-Positive Leukemias.

Varallo-Rodriguez C, Freyer CW Jr, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M.

Expert Opin Orphan Drugs. 2015;3(5):599-608. doi: 10.1517/21678707.2015.1036027. Epub 2015 Apr 16.

6.
7.

Resistant mutations in CML and Ph(+)ALL - role of ponatinib.

Miller GD, Bruno BJ, Lim CS.

Biologics. 2014 Oct 20;8:243-54. doi: 10.2147/BTT.S50734. eCollection 2014. Review.

8.

Supplemental Content

Loading ...
Support Center